- Molecular NameBimatoprost
- SynonymAGN 192024; bimatoprost
- Weight415.574
- Drugbank_IDDB00905
- ACS_NO155206-00-1
- Show 2D model
- LogP (experiment)2.436
- LogP (predicted, AB/LogP v2.0)2.86
- pkaN/A
- LogD (pH=7, predicted)2.86
- Solubility (experiment)Slightly soluble
- LogS (predicted, ACD/Labs)(ph=7)-3.68
- LogSw (predicted, AB/LogsW2.0)0.51
- Sw (mg/ml) (predicted, ACD/Labs)0.09
- No.of HBond Donors4
- No.of HBond Acceptors5
- No.of Rotatable Bonds12
- TPSA89.79
- StatusFDA approved
- AdministrationTopical (eye drops)
- PharmacologyA prostaglandin analog used topically (as eye drops) to control the progression of glaucoma and in the management of ocular hypertension. It reduces intraocular pressure (IOP) by increasing the outflow of aqueous fluid from the eyes.[1] It has also been used and prescribed off-label to lengthen eyelashes.
- Absorption_valueN/A
- Absorption (description)N/A
- Caco_2N/A
- BioavailabilityN/A
- Protein binding88.0
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmBimatoprost undergoes oxidation, N-deethylation and glucuronidation to form a variety of metabolites.
- Half lifeN/A
- ExcretionN/A
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityIn oral (by gavage) mouse and rat studies, doses up to 100 mg/kg/day did not produce any toxicity. This dose expressed as mg/m2 is at least 70 times higher than the accidental dose of one bottle of bimatoprost for a 10 kg child.
- LD50 (rat)N/A
- LD50 (mouse)N/A